The effect of tranexamic acid and hydroquinone in melasma

Comparison of the efficacy of intradermal injecting of tranexamix acid and hydroquinone cream in the treatment of melasma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180909040979N5

Enrollment

Registered

2020-01-03

Start date

2019-12-07

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma.

Interventions

Intervention 1: Intervention group 1: In group A, after application of topical anesthetic cream (lidocaine + prilocaine) 30 minutes before injection, tranexamic acid ampule, 100 mg/ml (manufactured by

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Female sex Being at the age of 18-50 years old Facial melasma

Exclusion criteria

Exclusion criteria: Pregnant and lactating women History of melasma treatment over the past month Active herpes simplex lesions on the face Sensitivity to the drugs in the study Coagulopathy Warts on the face Use of anticoagulant and anticonvulsant drugs Contraceptive use during the past 12 months and during the study

Design outcomes

Primary

Measure	Time frame
The degree of melasma treatment. Timepoint: Before treatment, at 4th, 8th and 12th week during the treatment and three months after the end of the treatment. Method of measurement: MASI score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMotahareh Babazadeh

Ahvaz University of Medical Sciences

Dr.pazyar@gmail.com+98 61 3292 1837

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026